查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1832114

血友病市場規模、佔有率、趨勢及預測（按類型、治療、療法和地區分類），2025 年至 2033 年

Hemophilia Market Size, Share, Trends and Forecast by Type, Treatment, Therapy, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球血友病市場規模達143.3億美元。展望未來， IMARC Group預測，到2033年，該市場規模將達到334.2億美元，2025-2033年期間的複合年成長率為9.37%。目前，北美佔據市場主導地位，2024年其市佔率將超過49.7%。由於對創新療法（包括基因療法和延長半衰期的療法）的投資增加，市場正在不斷擴張。同時，患者意識的提升和個人化醫療的進步持續推動市場發展，進一步支持了已開發地區和新興地區的血友病市場佔有率。

由於高額的研發投入，血友病市場發生了翻天覆地的變化。這些資金推動了基因療法等療法的創新，旨在為血友病患者提供持久的治療方案。隨著全球血友病病例的增加，人們努力改進治療方法，試圖降低因子替代療法的比率。事實上，延長半衰期療法就是這樣一種治療方法，它降低了患者的輸液率，從而提高了他們的生活品質。另一方面，個人化治療方法正在不斷發展，人們越來越傾向於個人化醫療，以確保治療更符合個別患者的特定需求。在美國，對晚期血友病治療的需求已經大幅成長，這主要是由於人們對更好、更簡單的治療方法的需求。

隨著血友病患者數量的增加，人們越來越關注那些能夠提高療效、減少輸液次數、最終改善患者生活品質的療法。基因療法有望提供長期或永久性的治療方案，並已引起廣泛關注，目前美國已有多項臨床試驗正在進行中。美國政府和醫療機構也對開放這些新療法的管道表現出更大的興趣，致力於推動這些療法的普及和價格的合理化。鑑於患者正在尋求替代傳統凝血因子替代療法（這些療法需要定期輸液）的方案，這一點尤其重要。此外，新型凝血因子濃縮物和非凝血因子療法的核准為患者提供了更好的治療選擇，減少了出血事件的發生，並降低了就診需求。

血友病市場趨勢：

血友病病例增加和進展

全球血友病和遺傳性疾病發生率的上升是推動全球血友病市場成長的關鍵驅動力。 2023年，全球近219,000人被診斷出患有血友病。診斷數量的增加，加上預防性治療的日益普及，代表著巨大的市場成長機會。此外，各政府機構正在進行宣傳活動，以提高人們對早期診斷和新生兒篩檢重要性的認知，這為該行業帶來了積極的成長前景。此外，有限的治療方案也推動了研發 (R&D) 投資的增加。該領域的領先公司正專注於開發先進的診斷工具和療法，旨在提高治療的有效性和準確性，從而提升市場潛力。此外，全球範圍內對建立專門血友病治療中心 (HTC) 的大量投資預計將進一步推動市場成長。例如，2023年，HTC 資助計畫為12個國家的20個中心提供了支持，加強了資料收集並改善了病患照護。

血友病基因治療的進展

隨著創新療法的湧現，全球血友病市場正在經歷重大變革，以應對長期存在的治療挑戰。傳統療法，例如頻繁的因子替代輸注，通常成本高昂，且患者依從性差。這導致對替代療法的需求日益成長，這些療法不僅能改善患者的預後，還能提供長期解決方案。基因療法的興起是最具前景的進展之一，它有可能消除定期輸注的需要，並為全球血友病患者提供更永續的治療模式。例如，2024年12月，印度首例利用慢病毒載體成功進行的重症血友病A的人體基因治療。這項突破性的治療實現了零出血事件，證明了其在長期預防出血方面的有效性。該療法還消除了重複輸注的需要，從而降低了患者的成本和負擔。這項成功凸顯了基因療法在血友病市場的未來潛力，使其成為改變治療格局的有力競爭者。隨著基因療法的蓬勃發展，預計其市場規模將大幅擴張，為全球血友病患者提供創新、經濟高效且長期有效的解決方案。隨著這一轉變，血友病市場趨勢將與市場對先進、永續治療方案日益成長的需求保持一致。

血友病治療的便利性與個人化

隨著全球血友病市場持續成長，人們越來越重視提供更大便利性和個人化的治療。許多目前的療法，尤其是靜脈輸液，非常耗時，需要頻繁就醫，並且可能給患者帶來不便。隨著以患者為中心的照護變得越來越重要，對透過簡單給藥和個人化治療方案來改善生活品質的療法的需求正在上升。這刺激了更易於獲取和對患者友好的治療方案的開發，進一步推動了血友病市場的創新。例如，2025 年 1 月，FDA 批准了 Concizumab-mtci (Alhemo)，這是第一個針對具有抑制劑的血友病 A 和 B 的皮下預防性治療。這種基於 3 期臨床試驗資料的新型治療方法透過提供皮下注射為患者提供了更便捷的選擇，無需靜脈輸液。 Alhemo 的核准對存在抑制劑的患者來說意義非凡，它為現有療法提供了急需的替代方案，並提升了血友病管理的靈活性和便利性。隨著這項新獲批，血友病市場正朝著不僅更有效，而且能夠根據患者個體需求量身定做的療法轉變，使治療更加便捷。因此，該市場正在快速擴張，為滿足全球血友病患者多樣化需求的個人化護理解決方案提供了更多機會。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 二手資料
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球血友病市場

  • 市場概況
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場細分：依類型

  • 血友病A
  • 血友病B
  • 血友病C
  • 其他

第7章：市場區隔：依治療方式

  • 一經請求
  • 預防

第8章：市場區隔：依療法

  • 替代療法
  • ITI 治療
  • 基因治療

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第 10 章：SWOT 分析

第 11 章：價值鏈分析

第 12 章：波特五力分析

第13章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Baxter International Inc.
    • Bayer AG
    • BioMarin Pharmaceutical Inc.
    • CSL Behring (CSL Limited)
    • F. Hoffmann-La Roche AG
    • Grifols SA
    • Kedrion SpA
    • Novo Nordisk A/S
    • Octapharma AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
Product Code: SR112025A4508

The global hemophilia market size was valued at USD 14.33 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 33.42 Billion by 2033, exhibiting a CAGR of 9.37% during 2025-2033. North America currently dominates the market, holding a significant market share of over 49.7% in 2024.The market is expanding due to increased investment in innovative therapies, including gene therapy and treatments with extended half-lives. At the same time, rising patient awareness and advancements in personalized medicine continue to drive the market, further supporting the hemophilia market share in both developed and emerging regions.

The market has undergone tremendous evolution on account of being subject to high R&D spending. The funding bestowed innovations in therapies such as gene therapies which purport to give solutions that would last such patients. Efforts have gone into enhancing treatments in an attempt to cut down factor replacement therapy rate as hemophilia cases are on the rise globally. With longer half-life treatment being one such treatment, in fact, it decreases the infusion rate for the patients to elevate their quality of life. Another aspect has been the personalized treatment methods that have been under development with growing inclination toward personalized medicine, ensuring that treatment cater more toward the particular needs of an individual patient. In the U.S., demand for advanced hemophilia treatment has picked up well, driven largely by the demand for better and easy methods of treatments.

As the population of individuals with hemophilia increases, there is a rising focus on therapies that offer improved efficacy and fewer infusions, ultimately enhancing patients' quality of life. Gene therapies, which offer the potential for long-term or permanent treatment solutions, have garnered significant attention, with several clinical trials underway in the country. The US government and healthcare centers have also expressed greater interest in opening up access to these new treatments, promoting treatments to become more accessible and affordable. This has been particularly significant as patients look for alternatives to conventional factor replacement treatments that take place regularly through infusions. Additionally, the approval of new clotting factor concentrates, and non-factor therapies has provided better management options for patients, allowing for fewer bleeding episodes and reducing the need for hospital visits.

Hemophilia Market Trends:

Increasing Hemophilia Cases and Advancements

The increasing worldwide incidence of hemophilia and genetic disorders are key drivers fuelling the global hemophilia market growth. In 2023, almost 219,000 individuals globally were diagnosed with hemophilia. The increasing number of diagnoses, combined with the growing adoption of prophylactic therapy, represents a huge opportunity for market growth. Additionally, various governmental bodies are conducting campaigns to raise awareness about the importance of early diagnosis and neonatal screening, which is fostering positive growth prospects for the industry. Furthermore, increased investment in research and development (R&D) is being driven by the limited treatment options available. Leading companies in the sector are focusing on developing advanced diagnostic tools and therapies that aim to improve treatment effectiveness and precision, boosting the market's potential. Moreover, substantial investments in the creation of specialized hemophilia treatment centers (HTCs) worldwide are expected to drive market growth further. For example, in 2023, the HTC Funding Program provided support to 20 centers across 12 countries, strengthening data collection and enhancing patient care.

Advancements in Gene Therapy for Hemophilia

The global hemophilia market is undergoing significant transformation as new and innovative therapies emerge to address longstanding challenges in treatment. Traditional approaches, such as frequent factor replacement infusions, often come with high costs and compliance issues for patients. This has led to an increasing demand for alternative therapies that not only improve patient outcomes but also provide long-term solutions. One of the most promising advancements is the rise of gene therapy, offering the potential to eliminate the need for regular infusions and provide a more sustainable treatment model for hemophilia patients worldwide. For instance, in December 2024, India's first human gene therapy for severe Hemophilia A was successfully conducted using a lentiviral vector. This groundbreaking treatment resulted in zero bleeding episodes, demonstrating its effectiveness in providing long-term protection against bleeding. The therapy also eliminated the need for repeated infusions, reducing both the cost and burden on patients. This success highlights the future potential of gene therapies in the hemophilia market, making them a strong contender in transforming the treatment landscape. As gene therapies gain traction, they are expected to significantly expand the market, offering an innovative, cost-effective, and long-term solution for hemophilia patients globally. With this shift, the hemophilia market trends are set to align with the growing demand for advanced, sustainable treatment options.

Convenience and Personalization in Hemophilia Treatments

As the global hemophilia market continues to grow, there is an increasing emphasis on treatments that offer greater convenience and personalization. Many current therapies, particularly intravenous infusions, are time-consuming, require frequent hospital visits, and can be inconvenient for patients. As patient-centric care becomes more important, the demand for therapies that improve quality of life through ease of administration and personalized treatment regimens is on the rise. This has spurred the development of more accessible and patient-friendly treatment options, further driving innovation in the hemophilia market. For instance, in January 2025, the FDA approved Concizumab-mtci (Alhemo), the first subcutaneous prophylactic treatment for Hemophilia A and B with inhibitors. This novel treatment, based on phase 3 clinical trial data, offers patients a more convenient option by providing a subcutaneous injection, eliminating the need for intravenous infusions. The approval of Alhemo is a game-changer for patients with inhibitors, providing a much-needed alternative to existing treatments and increasing the flexibility and convenience of managing hemophilia. With this new approval, the hemophilia market is witnessing a shift toward therapies that are not only more effective but also tailored to the individual needs of patients, making treatment more accessible. As a result, this market is expanding rapidly, with greater opportunities for personalized care solutions to address the diverse needs of hemophilia patients worldwide.

Hemophilia Industry Segmentation:

Analysis by Type:

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Others

As per the hemophilia market outlook, in 2024, the hemophilia A segment led the market, accounting for 75.3% of the total market share driven by higher prevalence of Hemophilia A compared to Hemophilia B, with more patients diagnosed with Factor VIII deficiency. Additionally, advancements in therapies specifically targeting Hemophilia A, such as gene therapy and improved clotting factor products, have contributed to this growth. The increasing diagnosis rate and the popularity of prophylactic treatments that prevent bleeding episodes have also played a critical role in driving the demand for Hemophilia A treatments. With the continued focus on developing more effective, long-lasting therapies, the Hemophilia A segment is expected to maintain its leading position in the global market.

Analysis by Treatment:

  • On-Demand
  • Prophylaxis

In 2024, the on-demand segment led the hemophilia market, driven by the preference for immediate intervention to manage bleeding episodes. On-demand therapy is primarily used to treat spontaneous bleeds and trauma, offering patients quick access to treatment when needed. This segment has gained traction due to its flexible and responsive nature, particularly for patients who experience occasional bleeding episodes. Additionally, the development of more advanced and easier-to-administer on-demand treatments, such as subcutaneous injections and extended-acting factor therapies, has enhanced patient compliance and convenience. As these therapies continue to improve in terms of effectiveness and ease of use, the on-demand treatment segment remains a crucial player in the Hemophilia market.

Analysis by Therapy:

  • Replacement Therapy
  • ITI Therapy
  • Gene Therapy

In 2024, the replacement therapy segment led the hemophilia market, accounting for 61.7% of the total market share, driven by the effectiveness of replacement therapies in treating both Hemophilia A and B. These therapies involve replacing the missing clotting factors (Factor VIII for Hemophilia A and Factor IX for Hemophilia B), directly addressing the root cause of bleeding episodes. With continuous advancements in the half-life of clotting factors, extended-acting therapies have gained preference, providing longer protection against bleeding episodes and reducing the frequency of infusions. The widespread use of prophylactic replacement therapy has also contributed to the segment's leading position, as it helps patients maintain better overall health and quality of life.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, the North America segment led the hemophilia market, accounting for 49.7% of the total market share, driven by its high healthcare expenditure, advanced healthcare infrastructure, and extensive access to innovative therapies. North America also benefits from a well-established network of specialized hemophilia treatment centers (HTCs) and significant government support for healthcare research and development. Furthermore, the presence of leading pharmaceutical companies developing innovative hemophilia treatments has contributed to the rapid adoption of novel therapies. The increased diagnosis rates, patient awareness, and access to newer treatments like gene therapy and extended-acting clotting factors have significantly boosted the demand for hemophilia care in North America, solidifying its position as the largest market.

Key Regional Takeaways:

United States Hemophilia Market Analysis

In 2024, the United States accounted for 93.50% of the hemophilia market in North America, driven by multiple factors. United States is a significant contributor to this market share owing to the increase in specialized hemophilia treatment centers (HTCs) across the country. As per the National Bleeding Disorders Foundation, approximately 141 federally funded treatment centers and programs are active in the US. These centers are integral in delivering comprehensive care, improving early diagnosis, and enhancing patient outcomes. The rise in public and private sector funding has led to the expansion of HTCs, ensuring more widespread access to advanced treatments. With continued investments in healthcare infrastructure and specialized care models, adoption rates of hemophilia therapies are steadily increasing. The growing presence of HTCs, combined with strategic collaborations between healthcare providers and pharmaceutical companies, strengthens the market by offering patients more reliable diagnosis and treatment options. This development continues to foster greater patient engagement and boosts the overall growth of the market.

Asia Pacific Hemophilia Market Analysis

The Asia-Pacific region is experiencing a notable rise in hemophilia adoption, largely driven by the increasing prevalence of genetic disorders in the area. According to the Tata Institute for Genetics and Society, there are 5000-8000 rare genetic diseases identified globally, with 450 cases reported in India. Hemophilia, particularly its genetic transmission through inherited X-linked recessive mutations, plays a significant role in the increasing patient population. Public health initiatives focusing on early detection, genetic counseling, and awareness campaigns have improved the identification of hemophilia patients. Advances in diagnostic technologies further contribute to the quicker identification of genetic markers related to the disease. Additionally, better healthcare frameworks and government support are promoting the management of hemophilia across the region. These factors combined with the growing attention to rare genetic conditions create a positive environment for expanding hemophilia care and interventions in Asia-Pacific.

Europe Hemophilia Market Analysis

Europe's aging population is influencing the growing demand for specialized hemophilia care, as more individuals are living longer with the condition. By the beginning of 2024, Europe's population was estimated at 449.3 Million, with over 20% aged 65 or older. As life expectancy rises, patients diagnosed with hemophilia in their early years continue to require lifelong treatment, leading to an increased demand for healthcare resources. This demographic shift is placing greater focus on managing age-related complications in hemophilia, such as joint damage and associated comorbidities. Healthcare systems are adapting to this change by refining long-term therapy plans and mobility support services. The rise in geriatric patients with hemophilia is prompting healthcare providers to tailor treatment approaches to meet the needs of elderly patients, ensuring consistent access to replacement therapies and rehabilitation, driving the demand for specialized services in the region.

Latin America Hemophilia Market Analysis

In Latin America, the adoption of hemophilia treatments is on the rise due to the growing number of diagnosed cases in the region. Government data from Colombia in 2021 reported a prevalence of hemophilia A of 4.29 cases per 100,000 people. The increasing number of diagnoses, along with better access to healthcare services, is helping to raise awareness of the disease burden. Population screening programs have been instrumental in identifying more individuals affected by hemophilia, which in turn has heightened the demand for consistent and comprehensive treatment plans. As more patients are diagnosed and healthcare access improves, the need for ongoing therapy and specialized care is driving the market's expansion in Latin America.

Middle East and Africa Hemophilia Market Analysis

In the Middle East and Africa, hemophilia treatment adoption is rising as regional healthcare infrastructure continues to expand. The prevalence of hemophilia in countries across the Middle East and North Africa (MENA) region-such as Iraq, Iran, Turkey, Egypt, Jordan, Syria, and Saudi Arabia-ranges from 1.4 to 8.1 per 100,000 people. Strengthening healthcare systems and the introduction of new therapy and diagnostic centers are improving access to specialized services and early detection. Advances in diagnostic capabilities and treatment options have contributed to greater hemophilia care availability in underserved regions. As healthcare infrastructure continues to improve, more patients are gaining access to effective treatments, resulting in increased adoption of hemophilia care across the Middle East and Africa.

Competitive Landscape:

As per the hemophilia market forecast, leading companies in the market are focusing on R&D to develop advanced formulations with better efficacy and fewer side effects, reflecting the shift toward safer and more effective treatments. Expansions through acquisitions, partnerships, and global collaborations are driving the market, enabling companies to access new markets and technologies. Regulatory compliance and sustainable manufacturing remain key priorities, underscoring their commitment to quality, safety, and environmental responsibility.

The report provides a comprehensive analysis of the competitive landscape in the hemophilia market with detailed profiles of all major companies, including:

  • Baxter International Inc.
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • CSL Behring (CSL Limited)
  • F. Hoffmann-La Roche AG
  • Grifols S.A.
  • Kedrion S.p.A.
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Key Questions Answered in This Report

  • 1.How big is the hemophilia market?
  • 2.What is the future outlook of hemophilia market?
  • 3.What are the key factors driving the hemophilia market?
  • 4.Which region accounts for the largest hemophilia market share?
  • 5.Which are the leading companies in the global hemophilia market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hemophilia Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Hemophilia A
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Hemophilia B
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Hemophilia C
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Treatment

  • 7.1 On-Demand
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Prophylaxis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Therapy

  • 8.1 Replacement Therapy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 ITI Therapy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Gene Therapy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Baxter International Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bayer AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 BioMarin Pharmaceutical Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 CSL Behring (CSL Limited)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 F. Hoffmann-La Roche AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 Grifols S.A.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Kedrion S.p.A.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Novo Nordisk A/S
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Octapharma AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 SWOT Analysis
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Sanofi S.A.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Takeda Pharmaceutical Company Limited
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hemophilia Market: Major Drivers and Challenges
  • Figure 2: Global: Hemophilia Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Hemophilia Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Hemophilia Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Hemophilia Market: Breakup by Treatment (in %), 2024
  • Figure 6: Global: Hemophilia Market: Breakup by Therapy (in %), 2024
  • Figure 7: Global: Hemophilia Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Hemophilia (Hemophilia A) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Hemophilia (Hemophilia A) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Hemophilia (Hemophilia B) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Hemophilia (Hemophilia B) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Hemophilia (Hemophilia C) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Hemophilia (Hemophilia C) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Hemophilia (Other Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Hemophilia (Other Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Hemophilia (On-Demand) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Hemophilia (On-Demand) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Hemophilia (Prophylaxis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Hemophilia (Prophylaxis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Hemophilia (Replacement Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Hemophilia (Replacement Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Hemophilia (ITI Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Hemophilia (ITI Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Hemophilia (Gene Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Hemophilia (Gene Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: North America: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: North America: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: United States: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: United States: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Canada: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Canada: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Asia-Pacific: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Asia-Pacific: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: China: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: China: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Japan: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Japan: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: India: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: India: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: South Korea: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: South Korea: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Australia: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Australia: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Indonesia: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Indonesia: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Others: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Others: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Europe: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Europe: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Germany: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Germany: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: France: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: France: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: United Kingdom: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: United Kingdom: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Italy: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Italy: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Spain: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Spain: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Russia: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Russia: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Others: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Others: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Latin America: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Latin America: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Brazil: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Brazil: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Mexico: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Mexico: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Others: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Others: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Middle East and Africa: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Middle East and Africa: Hemophilia Market: Breakup by Country (in %), 2024
  • Figure 74: Middle East and Africa: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Global: Hemophilia Industry: SWOT Analysis
  • Figure 76: Global: Hemophilia Industry: Value Chain Analysis
  • Figure 77: Global: Hemophilia Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hemophilia Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Hemophilia Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Hemophilia Market Forecast: Breakup by Treatment (in Million USD), 2025-2033
  • Table 4: Global: Hemophilia Market Forecast: Breakup by Therapy (in Million USD), 2025-2033
  • Table 5: Global: Hemophilia Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Hemophilia Market: Competitive Structure
  • Table 7: Global: Hemophilia Market: Key Players